Key terms

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AMGN news

Yesterday 12:25am ET BMO Capital Reaffirms Their Buy Rating on Amgen (AMGN) May 03 11:34am ET Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Kura Oncology (KURA) and Amgen (AMGN) May 03 11:13am ET Amgen price target raised to $325 from $315 at BofA May 03 11:09am ET Amgen price target lowered to $328 from $332 at RBC Capital May 03 9:55am ET Early notable gainers among liquid option names on May 3rd May 03 9:32am ET Amgen upgraded, Peloton downgraded: Wall Street’s top analyst calls May 03 9:13am ET Amgen price target raised to $310 from $271 at Morgan Stanley May 03 8:08am ET Oppenheimer Remains a Buy on Amgen (AMGN) May 03 8:06am ET Amgen (AMGN) Receives a Buy from Piper Sandler May 03 7:46am ET Amgen up due to positive obesity data, says Jefferies May 03 7:45am ET AMGN Earnings: Amgen Surges After Raised Forecast, Weight Loss Drug Update May 03 7:39am ET Amgen price target raised to $307 from $284 at UBS May 03 7:10am ET William Blair upgrades Amgen on confidence in upcoming obesity data May 03 7:07am ET Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN), Amgen (AMGN) and Omnicell (OMCL) May 03 6:47am ET Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH) May 03 6:43am ET RBC Capital Reaffirms Their Buy Rating on Amgen (AMGN) May 03 6:29am ET Amgen upgraded to Outperform from Market Perform at William Blair May 03 4:38am ET Amgen upgraded to Equal Weight from Underweight at Barclays May 02 4:05pm ET Arrowhead earns $50M milestone from Royalty Pharma May 02 4:03pm ET Amgen narrows FY24 adjusted EPS view to $19.00-$20.20 from $18.90-$20.30 May 02 4:01pm ET Amgen reports Q1 adjusted EPS $3.96, consensus $3.87 May 02 1:49pm ET Notable companies reporting after market close May 02 7:05am ET Options Volatility and Implied Earnings Moves Today, May 02, 2024 May 01 9:20am ET BMO sees CytomX rallying after ‘surprise’ data announcement Apr 30 8:01am ET Analysts’ Top Healthcare Picks: Laboratory (LH), Amgen (AMGN) Apr 30 7:56am ET Amgen settlement with Sandoz a positive, says Jefferies Apr 30 7:21am ET Amgen (AMGN) Gets a Buy from Truist Financial Apr 30 5:37am ET Sandoz, Amgen to resolve all patent disputes relating to denosumab biosimilars Apr 26 9:02am ET Amgen announces imminent submission of MAA to EMA for teprotumumab Apr 24 6:30am ET Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Bausch + Lomb Corporation (BLCO) Apr 22 8:27am ET Piper Sandler Sticks to Its Buy Rating for Amgen (AMGN)

No recent press releases are available for AMGN

AMGN Financials

1-year income & revenue

Key terms

AMGN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AMGN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms